ClearBridge Investments
EGRX

ClearBridge Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

ClearBridge Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-580
Closed -$27K – 1071
2020
Q1 		$27K Sell
580
-20
-3% -$1K ﹤0.01% 834
2019
Q4 		$36K Buy
+600
New +$35.8K ﹤0.01% 884

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ClearBridge Investments's EGRX Position: Q2 2020 in Review

ClearBridge Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 580 shares — an estimated $27K sold.

ClearBridge Investments first reported a position in EGRX in Q4 2019 and held it in 2 quarters. The position peaked at $36K in Q4 2019. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

  • ClearBridge Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • ClearBridge Investments sold 580 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $27K.
  • ClearBridge Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • ClearBridge Investments's Eagle Pharmaceuticals, Inc. position peaked at $36K in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on ClearBridge Investments's 13F filing for Q2 2020, filed 14 Aug 2020.